MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM
FDA Approval Based on Results of SEQUOIA-HCM
MYQORZO is Companys First FDA-App… [+17913 chars]
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - Cytokinetics
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference Call Today …
Source:Cytokinetics.com
Published:
Related News
Yen Extends Gains Amid Threat of Intervention: Markets Wrap - Bloomberg.com
The dollar fell against all of its major peers after a rate check Friday by the Federal Reserve Bank of New York spurred speculation the US may assist Japan in efforts to boost the yen. Gold rose above $5,000 for the first time and US stock futures dropped wi…
Bloomberg•Anand Krishnamoorthy, Ruth Carson
Dollar Pressure Mounts as Reasons for Further Weakness Multiply - Bloomberg.com
Bloomberg
Dow Jones Futures Fall; Trump Tariffs, Government Shutdown, Big Earnings In Focus - Investor's Business Daily
Shutdown risk, new Trump tariff threat, big earnings and a huge storm.
Investor's Business Daily